OKYO Pharma to present at Eyecelerator, share urcosimod data at ARVO annual meeting

OKYO Pharma Ltd (NASDAQ:OKYO) said its CEO Robert Dempsey will present at Eyecelerator on May 1 in Denver, while company leadership will also participate in the ARVO Annual Meeting from May 3 to 7.

The ARVO presentation will highlight first-in-human data for urcosimod, showing clinically meaningful pain reduction in neuropathic corneal pain patients. The investigational therapy has received FDA Fast Track designation.